Targeting IL-17 with ixekizumab in patients with psoriasis

TY - JOUR

T1 - Targeting IL-17 with ixekizumab in patients with psoriasis

AU - Dyring Andersen, Beatrice

AU - Skov, Lone

AU - Zachariae, Claus

PY - 2015/9

Y1 - 2015/9

N2 - Psoriasis is a multifactorial chronic inflammatory skin disease of unknown etiology. Knowledge of the pathophysiology of psoriasis has evolved and identified IL-17 as a key pro-inflammatory mediator in psoriasis creating new medical avenues. Several agents targeting IL-17 or its receptor are in clinical trials for the treatment of moderate-to-severe psoriasis. This review focuses on the biological rationale and the results of clinical trials with ixekizumab, a humanized IgG4 monoclonal antibody. The currently available Phase I to III data indicate that ixekizumab is a well-tolerated promising drug, although long-term data of efficacy and safety are needed before ixekizumab and other IL-17 targeting therapeutics can find their place in clinical practice.

AB - Psoriasis is a multifactorial chronic inflammatory skin disease of unknown etiology. Knowledge of the pathophysiology of psoriasis has evolved and identified IL-17 as a key pro-inflammatory mediator in psoriasis creating new medical avenues. Several agents targeting IL-17 or its receptor are in clinical trials for the treatment of moderate-to-severe psoriasis. This review focuses on the biological rationale and the results of clinical trials with ixekizumab, a humanized IgG4 monoclonal antibody. The currently available Phase I to III data indicate that ixekizumab is a well-tolerated promising drug, although long-term data of efficacy and safety are needed before ixekizumab and other IL-17 targeting therapeutics can find their place in clinical practice.

U2 - 10.2217/imt.15.63

DO - 10.2217/imt.15.63

M3 - Journal article

C2 - 26569072

SN - 1750-743X

VL - 7

SP - 957

EP - 966

JO - Immunotherapy

JF - Immunotherapy

IS - 9

ER -